Daniel A. Haber

109.1k citations

286 papers · 63.7k indexed · 28 hit papers · h-index 106

Impact in

Oncology top 0.01%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Cancer Research top 0.01%
- Cancer Genomics and Diagnostics

Papers in

Oncology 132
- Cancer Cells and Metastasis 61
- Cancer-related Molecular Pathways 24
Cancer Research 67
- Cancer Genomics and Diagnostics 58

Co-authors: Daphne W. Bell Shyamala Maheswaran Jeffrey Settleman Raffaella Sordella En Li Masaki Okano Thomas J. Lynch Brian W. Brannigan
Journals: Cancer Research (30 papers)Proceedings of the National Academy of Sciences (21 papers)Cell (17 papers)Clinical Cancer Research (13 papers)Genes & Development (11 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Daniel A. Haber

282 papers receiving 62.4k citations

Hit Papers

15 papers align trajectories log scale

Clusters of circulating tumor cells traverse capillary-sized vessels 2016 · 366 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Proceedings of the National Academy of Sciences
2015 Science
2014 Nature Protocols
2014 Cancer Discovery
2014 Cell
2013 Science
2012 Nature
2012 Nucleic Acids Research
2011 The Journal of Cell Biology
2008 Journal of Clinical Oncology
2008 New England Journal of Medicine
2007 Cell
2007 Nature
2007 Nature reviews. Cancer
2006 Proceedings of the National Academy of Sciences
2005 Proceedings of the National Academy of Sciences
2005 Journal of Clinical Oncology
2004 Science
2004 New England Journal of Medicine
2002 Cell
2001 Cell
1999 Cell
1999 Science
1999 Cell
1997 Cell
1991 Proceedings of the National Academy of Sciences
1990 Cell
1990 Cell

Peers

Countries citing papers authored by Daniel A. Haber

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Haber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Haber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Haber more than expected).

Fields of papers citing papers by Daniel A. Haber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Haber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Haber. The network helps show where Daniel A. Haber may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel A. Haber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Haber Line = papers co-authored together Daniel A. Haber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	MAPK7 Regulates EMT Features and Modulates the Generation of CTCs Molecular Cancer Research ·Sarah Javaid, Jianmin Zhang, Gromoslaw A. Smolen, Min Yu, Ben S. Wittner, Anurag Singh, Kshitij S. Arora, Marissa W. Madden, Rushil Desai, Matthew Zubrowski, Benjamin Schott, David T. Ting, Shannon L. Stott, Mehmet Toner, Shyamala Maheswaran, Toshi Shioda, Sridhar Ramaswamy, Daniel A. Haber	2015	35
2	Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors Science ·Rachel Litman Flynn, Kelli E. Cox, Maya Jeitany, Hiroaki Wakimoto, Alysia R. Bryll, Neil J. Ganem, Francesca Bersani, José Ramón Pineda, Mario L. Suvà, Cyril H. Benes, Daniel A. Haber, François D. Boussin, Lee Zou Hit paper breakdown →	2015	376
3	Bioengineered Implantable Scaffolds as a Tool to Study Stromal-Derived Factors in Metastatic Cancer Models Cancer Research ·Francesca Bersani, Jung Woo Lee, Min Yu, Robert Morris, Rushil Desai, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Biju Parekkadan	2014	51
4	Developing Standards for Breakthrough Therapy Designation in Oncology Clinical Cancer Research ·Sandra J. Horning, Daniel A. Haber, Wendy Selig, S. Percy Ivy, Samantha Roberts, Jeff Allen, Ellen V. Sigal, Charles L. Sawyers	2013	24
5	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma Science Translational Medicine ·Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John R. Walsh, Mari Mino–Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman	2013	110
6	Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition Science ·Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa Wells, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran Hit paper breakdown →	2013	1928
7	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer Cancer Discovery ·David T. Miyamoto, Richard J. Lee, Shannon L. Stott, David T. Ting, Ben S. Wittner, Matthew Ulman, Malgorzata E. Smas, Jenna B. Lord, Brian W. Brannigan, Julie Trautwein, Neil H. Bander, Chin‐Lee Wu, Lecia V. Sequist, Matthew R. Smith, Sridhar Ramaswamy, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	2012	217
8	The Predominant WT1 Isoform (+KTS) Encodes a DNA-Binding Protein Targeting the Planar Cell Polarity Gene Scribble in Renal Podocytes Molecular Cancer Research ·Julie Wells, Miguel N. Rivera, Woo‐Jae Kim, Kristen Starbuck, Daniel A. Haber	2010	21
9	Prevalence and Functional Analysis of Sequence Variants in the ATR Checkpoint Mediator Claspin Molecular Cancer Research ·Jianmin Zhang, Young‐Han Song, Brian W. Brannigan, Doke C.R. Wahrer, Taryn A. Schiripo, Patricia L. Harris, Sara M. Haserlat, Lindsey E. Ulkus, Kristen Shannon, Judy E. Garber, Matthew L. Freedman, Brian E. Henderson, Lee Zou, Dennis C. Sgroi, Daniel A. Haber, Daphne W. Bell	2009	12
10	Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors Cancer Research ·Ultan McDermott, Rachel Y. Ames, A. John Iafrate, Shyamala Maheswaran, Hannah Stubbs, Patricia Greninger, Kaitlin McCutcheon, Randy Milano, Angela Tam, Diana Lee, Laury Lucien, Brian W. Brannigan, Lindsey E. Ulkus, Xiaojun Ma, Mark G. Erlander, Daniel A. Haber, Sreenath V. Sharma, Jeffrey Settleman	2009	83
11	Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort Clinical Cancer Research ·Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Annuska M. Glas, Anitha Male, Sonika Dahiya, Karleen Habin, René Bernards, Daniel A. Haber, Laura J. van’t Veer, Sridhar Ramaswamy	2008	115
12	Negative Regulation of YAP by LATS1 Underscores Evolutionary Conservation of the Drosophila Hippo Pathway Cancer Research ·Jianmin Zhang, Gromoslaw A. Smolen, Daniel A. Haber	2008	211
13	Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma Cancer Research ·Clara Montagut, Sreenath V. Sharma, Toshi Shioda, Ultan McDermott, Matthew Ulman, Lindsey E. Ulkus, Dora Dias‐Santagata, Hannah Stubbs, Diana Lee, Anurag Singh, Lisa Drew, Daniel A. Haber, Jeffrey Settleman	2008	405
14	Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors Cancer Research ·Ultan McDermott, A. John Iafrate, Nathanael S. Gray, Toshi Shioda, Marie Classon, Shyamala Maheswaran, Wenjun Zhou, Hwan Geun Choi, Shannon L. Smith, Lori Dowell, Lindsey E. Ulkus, Georgiana Kuhlmann, Patricia Greninger, James G. Christensen, Daniel A. Haber, Jeffrey Settleman	2008	312
15	Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib Cancer Research ·Roseann Mulloy, Audrey Ferrand, Young‐Joo Kim, Raffaella Sordella, Daphne W. Bell, Daniel A. Haber, Karen S. Anderson, Jeffrey Settleman	2007	150
16	Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation Cancer Research ·Nadia Godin-Heymann, Ianthe Bryant, Miguel N. Rivera, Lindsey Ulkus, Daphne W. Bell, David J. Riese, Jeffrey Settleman, Daniel A. Haber	2007	120
17	An X Chromosome Gene, WTX , Is Commonly Inactivated in Wilms Tumor Science ·Miguel N. Rivera, Woo‐Jae Kim, Julie Wells, David R. Driscoll, Brian W. Brannigan, Moonjoo Han, James C. Kim, Andrew P. Feinberg, William L. Gerald, Sara O. Vargas, Lynda Chin, A. John Iafrate, Daphne W. Bell, Daniel A. Haber	2007	225
18	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	2006	491
19	Sequence Variations of MicroRNAs in Human Cancer: Alterations in Predicted Secondary Structure Do Not Affect Processing Cancer Research ·Sven Diederichs, Daniel A. Haber	2006	139
20	Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science ·Raffaella Sordella, Daphne W. Bell, Daniel A. Haber, Jeffrey Settleman Hit paper breakdown →	2004	1337

About Daniel A. Haber

Daniel A. Haber is a scholar working on Oncology, Cancer Research, Aging, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 286 papers that have together received 63.7k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (61 papers), Cancer Genomics and Diagnostics (58 papers), Renal and related cancers (53 papers), Lung Cancer Treatments and Mutations (35 papers), DNA Repair Mechanisms (29 papers), Cancer-related Molecular Pathways (24 papers), 3D Printing in Biomedical Research (19 papers) and Microfluidic and Bio-sensing Technologies (19 papers). The work is most often cited by research in Oncology (26.3k citations), Cancer Research (14.0k citations), Pulmonary and Respiratory Medicine (19.4k citations), Molecular Biology (35.1k citations) and Cell Biology (4.4k citations). Daniel A. Haber has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Daphne W. Bell, Shyamala Maheswaran, Jeffrey Settleman, Raffaella Sordella, En Li, Masaki Okano, Thomas J. Lynch, Brian W. Brannigan, Mehmet Toner and Sreenath V. Sharma. Their work appears in journals such as Cancer Research, Proceedings of the National Academy of Sciences, Cell, Clinical Cancer Research and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact